New Research Identifies Metabolic Enzyme as Potential Target for Parkinson’s Treatment
Researchers have uncovered a metabolic mechanism within nerve cells that could pave the way for innovative treatments for Parkinson’s disease. A new study suggests that targeting the way cells process fats may assist reduce the neuronal damage associated with the condition.
The study, conducted by scientists at Nanyang Technological University in Singapore and published in the journal Nature Communications, identifies an enzyme called glycerol-3-phosphate acyltransferase (GPAT) as a key driver in the progression of the disease. According to the findings, GPAT—which is involved in the production of fats—amplifies the toxic effects of alpha-synuclein, a protein that typically accumulates in the brains of those living with Parkinson’s.
The research indicates that GPAT alters how nerve cells process lipids, which in turn damages the mitochondria. Because mitochondria are responsible for producing the energy required for cellular function, this interference reduces the cell’s energy capacity and increases the overall toxicity of alpha-synuclein. This creates a cumulative negative effect on the health and survival of nerve cells.
To test this theory, researchers conducted laboratory experiments using fruit flies and cultured mouse brain cells. The results demonstrated that reducing the activity of the GPAT enzyme led to a measurable decrease in nerve cell damage across both models.
This discovery suggests that focusing on lipid metabolism could be a viable therapeutic strategy. By targeting the GPAT enzyme, future medical interventions may be able to mitigate the cellular deterioration that characterizes the disease. Understanding these metabolic pathways is a critical step toward developing therapies that can protect neurons and potentially alter the course of the illness.
For more detailed information on this discovery, you can read the original report via Digi24.
